Ionis Pharmaceuticals, Inc. Common Stock (IONS) Price and Market Data

Ionis Pharmaceuticals, Inc. is a leading innovator in antisense technology, focused on discovering and developing novel medicines. The company maintains a broad clinical and preclinical pipeline targeting a wide range of diseases, with particular emphasis on cardiovascular, metabolic, neurological, and rare disorders. Ionis and Biogen launched Spinraza in 2016 for spinal muscular atrophy, while Biogen introduced the ALS treatment Qalsody in 2023. Through its cardiovascular-focused subsidiary Akcea, Ionis also brought Tegsedi for ATTR amyloidosis to market in 2018 and launched Waylivra in Europe in 2019. In 2024, Ionis and AstraZeneca launched Wainua for polyneuropathy. The company achieved its first two independent product launches in 2025 with Tryngolza for FCS and Dawnzera for HAE.